Elixir utilizes the powerful macrocyclic lactone class of drugs, which have established safety and efficacy profiles. This family of drugs is the most widely used for drug eluting stent applications.
Novolimus, a metabolite of sirolimus, was developed internally by Elixir for use in site-specific therapies.
Elixir also has a license to Myolimus, a Novartis Pharma AG compound. The co-exclusive license grants Elixir worldwide rights to utilize the Myolimus with Elixir's vascular as well as other site-specific drug-delivery applications. In addition, Elixir has an exclusive worldwide license for use of Myolimus in fully bioresorbable stents.
Novolimus is a novel mTOR inhibitor macrocyclic lactone with anti-proliferative and anti-inflammatory properties developed by Elixir for site specific therapies. The macrocyclic lactone drugs represent the most widely utilized drug family for drug eluting stent applications and have an established safety and efficacy profile.
Novolimus is an active metabolite of Sirolimus. Sirolimus is the most widely known mTOR inhibitor with a well-established safety and effectiveness profile in various treatment applications such as drug eluting stents, transplant, and oncology. Patients treated with Sirolimus orally or via DES implantation are exposed to significant amounts of Novolimus.
Elixir conducted five separate trials which included over 400 patients for the prevention of restenosis using Desyne, Desyne BD and a fully resorbable scaffold- Desolve resulting in excellent and sustained safety and effectiveness clinical outcomes.
Myolimus, a novel mTOR inhibitor macrocyclic lactone has demonstrated impressive versatility, stability, and a broad therapeutic index. The macrocyclic lactone drugs represent the most widely utilized drug family for drug eluting stent applications and have an established safety and efficacy profile. Myolimus can be used in a broad range of site–specific drug delivery therapeutic applications including a fully biodegradable stent program.
Myolimus First-in-Man Clinical Trials
Elixir has completed three separate first-in-man clinical studies evaluating the therapeutic effectiveness of the company’s Myolimus-eluting coronary stent systems. These studies used the company’s proprietary stent platform and three proprietary polymer technologies. In the first study, the stent platform incorporates a proprietary durable polymer coating with an established safety profile designed to have a minimal polymer load and the lowest known "olimus" drug dose. In the second study, the stent platform incorporates a proprietary biodegradable polymer coating designed to biodegrade within three to six months. In the third study, the stent platform incorporates a different proprietary biodegradable polymer coating designed to biodegrade within six to nine months.